258 related articles for article (PubMed ID: 33626345)
21. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Amato KR; Wang S; Tan L; Hastings AK; Song W; Lovly CM; Meador CB; Ye F; Lu P; Balko JM; Colvin DC; Cates JM; Pao W; Gray NS; Chen J
Cancer Res; 2016 Jan; 76(2):305-18. PubMed ID: 26744526
[TBL] [Abstract][Full Text] [Related]
22. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
23. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
24. LINC00346 promotes hepatocellular carcinoma progression via activating the JAK-STAT3 signaling pathway.
Yin YZ; Zheng WH; Zhang X; Chen YH; Tuo YH
J Cell Biochem; 2020 Jan; 121(1):735-742. PubMed ID: 31478228
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation.
Ding H; Liu J; Zou R; Cheng P; Su Y
J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
[TBL] [Abstract][Full Text] [Related]
27. Silencing
Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
[TBL] [Abstract][Full Text] [Related]
28. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
[TBL] [Abstract][Full Text] [Related]
29. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways.
Gao J; Xia R; Chen J; Gao J; Luo X; Ke C; Ren C; Li J; Mi Y
Aging (Albany NY); 2020 Apr; 12(7):6240-6259. PubMed ID: 32276266
[TBL] [Abstract][Full Text] [Related]
31. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
[TBL] [Abstract][Full Text] [Related]
32. IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment.
Zheng X; Xu M; Yao B; Wang C; Jia Y; Liu Q
Cell Signal; 2016 Sep; 28(9):1314-1324. PubMed ID: 27297362
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
Tan W; Zhu S; Cao J; Zhang L; Li W; Liu K; Zhong J; Shang C; Chen Y
Oncol Res; 2017 Nov; 25(9):1543-1553. PubMed ID: 28276313
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.
Wu L; Zhou J; Zhou W; Huang XF; Chen Q; Wang W; Zhai L; Li S; Tang Z
Pathol Res Pract; 2021 Apr; 220():153270. PubMed ID: 33640712
[TBL] [Abstract][Full Text] [Related]
35. miR-30e acts as a tumor suppressor in hepatocellular carcinoma partly via JAK1/STAT3 pathway.
Mao J; Hu X; Pang P; Zhou B; Li D; Shan H
Oncol Rep; 2017 Jul; 38(1):393-401. PubMed ID: 28560434
[TBL] [Abstract][Full Text] [Related]
36. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.
Zhao H; Guo Y; Li S; Han R; Ying J; Zhu H; Wang Y; Yin L; Han Y; Sun L; Wang Z; Lin Q; Bi X; Jiao Y; Jia H; Zhao J; Huang Z; Li Z; Zhou J; Song W; Meng K; Cai J
Oncotarget; 2015 Oct; 6(31):31927-43. PubMed ID: 26376676
[TBL] [Abstract][Full Text] [Related]
37. Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells.
Chen CT; Liao LZ; Lu CH; Huang YH; Lin YK; Lin JH; Chow LP
Exp Mol Med; 2020 Mar; 52(3):497-513. PubMed ID: 32203105
[TBL] [Abstract][Full Text] [Related]
38. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
Xia P; Zhang H; Xu K; Jiang X; Gao M; Wang G; Liu Y; Yao Y; Chen X; Ma W; Zhang Z; Yuan Y
Cell Death Dis; 2021 Jul; 12(7):691. PubMed ID: 34244479
[TBL] [Abstract][Full Text] [Related]
39. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]